Cargando…
Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants
INTRODUCTION: Melatonin is a hormone used in the treatment of diverse pathologies due to its ability to regulate numerous physiological processes related to biological rhythms and neuroendocrine function. MATERIAL AND METHODS: This study examines whether or not the antioxidant capacities of melatoni...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286327/ https://www.ncbi.nlm.nih.gov/pubmed/32542090 http://dx.doi.org/10.5114/aoms.2020.94106 |
_version_ | 1783544858111115264 |
---|---|
author | Muñoz, Herminia García, Sergio Ruiz, Adolfina |
author_facet | Muñoz, Herminia García, Sergio Ruiz, Adolfina |
author_sort | Muñoz, Herminia |
collection | PubMed |
description | INTRODUCTION: Melatonin is a hormone used in the treatment of diverse pathologies due to its ability to regulate numerous physiological processes related to biological rhythms and neuroendocrine function. MATERIAL AND METHODS: This study examines whether or not the antioxidant capacities of melatonin are modified during the creation of fast disintegrating oral tablets (FDDTs) through direct compression in which different concentrations of the active substance (3, 5, 10 and 60 mg) and excipients are made. In addition, the antioxidant capacity of melatonin is compared with that of reference antioxidants such as vitamin C, Trolox, resveratrol, glutathione and nicotinamide adenine dinucleotide phosphate (NADPH). RESULTS: Melatonin has a lower antioxidant capacity only 5% of the capacity of resveratrol. Resveratrol is the compound having the greatest antioxidant capacity. As for the influence of the tablets components, it was found that only at higher concentrations of melatonin (60 mg/tablet), with the excipients mannitol, polyvinylpyrrolidone (crospovidone), magnesium stearate and anhydrous colloidal silica, did a decrease occur in the antioxidant capacity value, possibly due to the lower percentage of these excipients in the formulation. |
format | Online Article Text |
id | pubmed-7286327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-72863272020-06-14 Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants Muñoz, Herminia García, Sergio Ruiz, Adolfina Arch Med Sci Clinical Research INTRODUCTION: Melatonin is a hormone used in the treatment of diverse pathologies due to its ability to regulate numerous physiological processes related to biological rhythms and neuroendocrine function. MATERIAL AND METHODS: This study examines whether or not the antioxidant capacities of melatonin are modified during the creation of fast disintegrating oral tablets (FDDTs) through direct compression in which different concentrations of the active substance (3, 5, 10 and 60 mg) and excipients are made. In addition, the antioxidant capacity of melatonin is compared with that of reference antioxidants such as vitamin C, Trolox, resveratrol, glutathione and nicotinamide adenine dinucleotide phosphate (NADPH). RESULTS: Melatonin has a lower antioxidant capacity only 5% of the capacity of resveratrol. Resveratrol is the compound having the greatest antioxidant capacity. As for the influence of the tablets components, it was found that only at higher concentrations of melatonin (60 mg/tablet), with the excipients mannitol, polyvinylpyrrolidone (crospovidone), magnesium stearate and anhydrous colloidal silica, did a decrease occur in the antioxidant capacity value, possibly due to the lower percentage of these excipients in the formulation. Termedia Publishing House 2020-04-05 /pmc/articles/PMC7286327/ /pubmed/32542090 http://dx.doi.org/10.5114/aoms.2020.94106 Text en Copyright © 2020 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Clinical Research Muñoz, Herminia García, Sergio Ruiz, Adolfina Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title | Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title_full | Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title_fullStr | Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title_full_unstemmed | Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title_short | Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
title_sort | contribution to determining the antioxidant capacity of melatonin in orodispersible tablets – comparison with reference antioxidants |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286327/ https://www.ncbi.nlm.nih.gov/pubmed/32542090 http://dx.doi.org/10.5114/aoms.2020.94106 |
work_keys_str_mv | AT munozherminia contributiontodeterminingtheantioxidantcapacityofmelatonininorodispersibletabletscomparisonwithreferenceantioxidants AT garciasergio contributiontodeterminingtheantioxidantcapacityofmelatonininorodispersibletabletscomparisonwithreferenceantioxidants AT ruizadolfina contributiontodeterminingtheantioxidantcapacityofmelatonininorodispersibletabletscomparisonwithreferenceantioxidants |